20-22 June, 2022
ENYO Pharma was participating as a member of the EIC Growth Club in Tech Tour Health 2022 to secure growth, exchange international contacts and build long-lasting relations with some of the most active investors and other innovators in Healthcare space.
3-4 June, 2022
ENYO Pharma was attending AASLD-EASL HBV Endpoints 2022 to share news on therapeutic endpoints, trial designs and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D. It was a great opportunity to meet academic, regulatory, pharmaceutical communities and patients in liver disease area.
30 May-2 June, 2022
ENYO Pharma and its collaborators were presenting the last results on Vonafexor’s effect in HBV at The Science of HBV Cure Meeting organized by Singapore Hepatology Conference.
“Antiviral effects of oral farnesoid X receptor agonist Vonafexor combined with pegylated interferon alpha2a in untreated patients with chronic hepatitis B”.
16-18 May, 2022
ENYO Pharma will attend the 22nd Bio€quity Europe, the Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs.
ENYO Pharma’s team will reconnect with investors and partners to accelerate the clinical development of its lead compound Vonafexor focused on kidney and liver diseases.
Jacky Vonderscher will also present “VONAFEXOR, a fibrolytic and anti-inflammatory for the treatment of kidney and liver diseases” in the Hot Topics Track #1 session,
23-25 March 2022
Jacky Vonderscher will attend the Tech Tour Future22 event, one of a series of EIC ScalingUp Roadshow events, and give a pitch about ENYO Pharma.
1,000 investors challenged over 1,000 selected tech entrepreneurs in 2021 over multiple sessions to level up their investment and growth. This event will allow us to meet the top only, to collaborate with Europe’s leading tech entrepreneurs and investors on future ambitions.